thymosin fraction 5

composed of group of polypeptides ranging in MW from 1000-15,000; these polypeptides act individually, sequentially or in concert to influence development & maintenance of T cell immunity; see also record for thymosin alpha(1) which is one of the polypeptides of fraction V; fraction 5A also contains polypeptides of MW less than 15,000

Also Known As:

Networked: 52 relevant articles (3 outcomes, 12 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hannappel, Ewald: 1 article (01/2003)
2.	Huff, Thomas: 1 article (01/2003)
3.	Bowman, K L: 1 article (01/2000)
4.	Farrimond, D D: 1 article (01/2000)
5.	Pompilius, M: 1 article (01/2000)
6.	Spangelo, B L: 1 article (01/2000)

Related Diseases

1.	Wasting Syndrome (Wasting Disease) 08/01/1980 - "Two pups in the litter developed a wasting syndrome and responded well to therapy with thymosin fraction 5. One pup that survived the wasting syndrome had a significant (P < 0.05) depression of its lymphocyte blastogenic response to phytohemagglutinin compared with its surviving littermates. " 05/01/1987 - "At least one form of wasting syndrome in puppies (immunodeficient dwarfism) has been found to respond to short-term therapy with a thymus hormone (thymosin fraction 5) or with bovine growth hormone (which is thymotropic) in limited clinical trials. "
2.	Chronic Hepatitis B 09/01/1991 - "We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. "
3.	Infections 01/01/1983 - "Administration of thymosin fraction 5 beginning on the day of infection greatly increased the resistance of the susceptible strains to infection, but decreased the resistance of the resistant strains. " 01/01/1983 - "Thymosin alpha 1 was effective in some infections at 0.4-400 micrograms/kg/day IP, about 1/100 of the dose required for thymosin fraction 5. Activity was also demonstrated against L-monocytogenes and Ps. " 01/01/1984 - "When the alloxan diabetic mice were inoculated daily intraperitoneally with thymosin fraction 5, beginning 3 days before infection, resistance to infection was greatly enhanced. "
4.	Neoplasms (Cancer) 07/01/1982 - "The results showed significantly retarded tumor growth (P less than 0.001) and prolonged survival time (P less than 0.001) when thymosin fraction V was used. " 12/01/1980 - "Thymosin fraction 5 can induce the appearance of suppressor T cells capable of regulating the in vitro generation of cytotoxic T lymphocytes (CTL) in a 5-day allogeneic or syngeneic mixed lymphocyte-tumor culture (MLTC). " 01/01/1976 - "Thymosin, fraction V, prepared by the method of Goldstein et al., was studied in in vitro lymphocyte cultures with cells obtained from normal subjects and patients with disseminated cancer. " 01/01/1984 - "Thymosin fraction 5 has been used in most clinical trials reported to date, including children with immunodeficiency disease and patients with autoimmune diseases and cancer. " 01/01/1980 - "Recent clinical studies with thymosin fraction 5 have shown therapeutic potentials for treatment of patients with primary immunodeficiency diseases and cancer."
5.	Urinary Bladder Neoplasms (Bladder Cancer) 10/18/1999 - "In this study, the antiproliferative activity of 5'-dFUrd used in combination with thymosin fraction 5 (TF5) was investigated in mouse bladder cancer cell line MBT-2 in vitro and in vivo. " 01/01/1990 - "Restorative effects of thymosin fraction 5 on reduction in responsiveness of rat thymocytes to allogenic lymphocytes during bladder tumor induction." 03/01/1985 - "Thymus lymphocytes in rats during induction of bladder tumors and effects of thymosin fraction 5 in vitro." 10/18/1999 - "Augmentation of antitumor activity of 5'-deoxy-5-fluorouridine by thymosin fraction 5 in mouse bladder cancer cells in vitro and in vivo." 02/01/1987 - "Reduction in responsiveness of thymocytes to phytohemagglutinin during bladder tumor induction and restorative effects of thymosin fraction 5 in rats."

Related Drugs and Biologics

1.	Thymalfasin
2.	Phytohemagglutinins
3.	Hormones (Hormone)
4.	Thymopentin
5.	Mitogens
6.	Thymopoietins (TP 49)
7.	Enzymes
8.	bovine growth hormone
9.	Interleukin-2 (IL2)
10.	Thymosin

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Combined Modality Therapy
4.	Thymectomy
5.	Remission Induction